Literature DB >> 10816561

Ligand interactions in the adenosine nucleotide-binding domain of the Hsp90 chaperone, GRP94. I. Evidence for allosteric regulation of ligand binding.

M F Rosser1, C V Nicchitta.   

Abstract

X-ray crystallographic studies of the N-terminal domain of Hsp90 have identified an unconventional ATP binding fold, thereby inferring a role for ATP in the regulation of the Hsp90 activity. In this report, N-ethylcarboxamidoadenosine (NECA) was used to investigate the nucleotide binding properties of GRP94, the endoplasmic reticulum paralog of Hsp90. Whereas Hsp90 did not bind NECA, GRP94 bound NECA in a saturable manner with a K(d) of 200 nm. NECA binding to GRP94 was efficiently blocked by geldanamycin and radicicol. Analysis of ligand binding stoichiometries by radioligand and calorimetric techniques indicated that GRP94 bound 1 mol of NECA/mol of GRP94 dimer. In contrast, GRP94 bound radicicol at a stoichiometry of 2 mol of radicicol/mol of GRP94 dimer. In [(3)H]NECA displacement assays, GRP94 displayed binding interactions with ATP, dATP, ADP, AMP, cAMP, and adenosine, but not GTP, CTP, or UTP. To accommodate the 0.5 mol of NECA:mol of GRP94 binding stoichiometry observed for the native GRP94 dimer, a model for allosteric regulation (negative cooperativity) of ligand binding is proposed. A hypothesis on the regulation of GRP94 conformation and activity by adenosine-based ligand(s) other than ATP and ADP is presented.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10816561     DOI: 10.1074/jbc.M001477200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Identification of novel quaternary domain interactions in the Hsp90 chaperone, GRP94.

Authors:  Feixia Chu; Jason C Maynard; Gabriela Chiosis; Christopher V Nicchitta; Alma L Burlingame
Journal:  Protein Sci       Date:  2006-06       Impact factor: 6.725

2.  Cytosolic chaperones influence the fate of a toxin dislocated from the endoplasmic reticulum.

Authors:  Robert A Spooner; Philip J Hart; Jonathan P Cook; Paola Pietroni; Christian Rogon; Jörg Höhfeld; Lynne M Roberts; J Michael Lord
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-06       Impact factor: 11.205

3.  Structure-activity relationship in a purine-scaffold compound series with selectivity for the endoplasmic reticulum Hsp90 paralog Grp94.

Authors:  Hardik J Patel; Pallav D Patel; Stefan O Ochiana; Pengrong Yan; Weilin Sun; Maulik R Patel; Smit K Shah; Elisa Tramentozzi; James Brooks; Alexander Bolaender; Liza Shrestha; Ralph Stephani; Paola Finotti; Cynthia Leifer; Zihai Li; Daniel T Gewirth; Tony Taldone; Gabriela Chiosis
Journal:  J Med Chem       Date:  2015-04-22       Impact factor: 7.446

Review 4.  The Chemical Biology of Molecular Chaperones--Implications for Modulation of Proteostasis.

Authors:  Kristoffer R Brandvold; Richard I Morimoto
Journal:  J Mol Biol       Date:  2015-05-21       Impact factor: 5.469

5.  Development of radamide analogs as Grp94 inhibitors.

Authors:  Aaron Muth; Vincent Crowley; Anuj Khandelwal; Sanket Mishra; Jinbo Zhao; Jessica Hall; Brian S J Blagg
Journal:  Bioorg Med Chem       Date:  2014-06-12       Impact factor: 3.641

6.  Structure Based Design of a Grp94-Selective Inhibitor: Exploiting a Key Residue in Grp94 To Optimize Paralog-Selective Binding.

Authors:  Nanette L S Que; Vincent M Crowley; Adam S Duerfeldt; Jinbo Zhao; Caitlin N Kent; Brian S J Blagg; Daniel T Gewirth
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

7.  A Human Variant of Glucose-Regulated Protein 94 That Inefficiently Supports IGF Production.

Authors:  Michal Marzec; Colin P Hawkes; Davide Eletto; Sarah Boyle; Ron Rosenfeld; Vivian Hwa; Jan M Wit; Hermine A van Duyvenvoorde; Wilma Oostdijk; Monique Losekoot; Oluf Pedersen; Bu Beng Yeap; Leon Flicker; Nir Barzilai; Gil Atzmon; Adda Grimberg; Yair Argon
Journal:  Endocrinology       Date:  2016-03-16       Impact factor: 4.736

8.  5'-N-ethylcarboxamidoadenosine is not a paralog-specific Hsp90 inhibitor.

Authors:  Shanshan Liu; Timothy O Street
Journal:  Protein Sci       Date:  2016-10-04       Impact factor: 6.725

9.  Experimental Anti-Inflammatory Drug Semapimod Inhibits TLR Signaling by Targeting the TLR Chaperone gp96.

Authors:  Jin Wang; Anatoly V Grishin; Henri R Ford
Journal:  J Immunol       Date:  2016-05-18       Impact factor: 5.422

10.  Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series.

Authors:  Tony Taldone; Pallav D Patel; Maulik Patel; Hardik J Patel; Christopher E Evans; Anna Rodina; Stefan Ochiana; Smit K Shah; Mohammad Uddin; Daniel Gewirth; Gabriela Chiosis
Journal:  J Med Chem       Date:  2013-08-21       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.